PH12015500282B1 - N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug - Google Patents

N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug Download PDF

Info

Publication number
PH12015500282B1
PH12015500282B1 PH12015500282A PH12015500282A PH12015500282B1 PH 12015500282 B1 PH12015500282 B1 PH 12015500282B1 PH 12015500282 A PH12015500282 A PH 12015500282A PH 12015500282 A PH12015500282 A PH 12015500282A PH 12015500282 B1 PH12015500282 B1 PH 12015500282B1
Authority
PH
Philippines
Prior art keywords
mmol
acetohydrazide
indol
compound
synthesis
Prior art date
Application number
PH12015500282A
Other languages
English (en)
Other versions
PH12015500282A1 (en
Inventor
Hojin Choi
Jaewon Lee
Changgon Lee
Nina Ha
Su Kil Seo
Sunmi Lee
Song-Min Lee
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Univ Inje Ind Acad Coop Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp, Univ Inje Ind Acad Coop Found filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of PH12015500282A1 publication Critical patent/PH12015500282A1/en
Publication of PH12015500282B1 publication Critical patent/PH12015500282B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
PH12015500282A 2012-08-30 2015-02-09 N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug PH12015500282B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120095729 2012-08-30
KR20120108972 2012-09-28
PCT/KR2013/007751 WO2014035149A1 (en) 2012-08-30 2013-08-29 N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug

Publications (2)

Publication Number Publication Date
PH12015500282A1 PH12015500282A1 (en) 2015-04-27
PH12015500282B1 true PH12015500282B1 (en) 2015-04-27

Family

ID=50183887

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015500282A PH12015500282B1 (en) 2012-08-30 2015-02-09 N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug

Country Status (15)

Country Link
US (1) US9447083B2 (enExample)
EP (1) EP2890677B1 (enExample)
JP (1) JP6139682B2 (enExample)
KR (1) KR101561987B1 (enExample)
CN (1) CN104755460B (enExample)
AU (1) AU2013309723B2 (enExample)
BR (1) BR112015004432A2 (enExample)
CA (1) CA2881797C (enExample)
ES (1) ES2651312T3 (enExample)
IN (1) IN2015MN00411A (enExample)
MX (1) MX368381B (enExample)
NZ (1) NZ704807A (enExample)
PH (1) PH12015500282B1 (enExample)
RU (1) RU2622651C2 (enExample)
WO (1) WO2014035149A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106986789B (zh) * 2016-01-20 2019-07-16 中国人民解放军军事医学科学院生物医学分析中心 对苯二酚类化合物及其制备方法与在抗肿瘤或免疫调节中的应用
CA3114565A1 (en) * 2018-09-28 2020-04-02 Nissan Chemical Corporation Additive for medium for promoting production of paracrine factor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
DE102004037515A1 (de) 2003-08-22 2005-03-17 Merck Patent Gmbh Verfahren zur Herstellung von Aldehyden
CA2608243A1 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Acyl hydrazones for treating cardiovascular diseases
BRPI0809498A2 (pt) * 2007-04-02 2014-09-23 Inst Oneworld Health Compostos inibidores de cftr e seus usos
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009155362A1 (en) 2008-06-19 2009-12-23 Ligand Pharmaceuticals Inc. Small molecule hematopoietic growth factor mimetic compounds and their uses
WO2013032907A1 (en) 2011-08-26 2013-03-07 The Broad Institute, Inc. Compounds and methods for the treatment of cancer stem cells

Also Published As

Publication number Publication date
EP2890677A1 (en) 2015-07-08
MX2015002601A (es) 2015-09-29
NZ704807A (en) 2016-06-24
JP6139682B2 (ja) 2017-05-31
RU2015105511A (ru) 2016-10-20
WO2014035149A1 (en) 2014-03-06
US9447083B2 (en) 2016-09-20
CN104755460B (zh) 2017-05-10
KR20140029318A (ko) 2014-03-10
US20150252030A1 (en) 2015-09-10
JP2015526508A (ja) 2015-09-10
PH12015500282A1 (en) 2015-04-27
AU2013309723B2 (en) 2016-07-14
BR112015004432A2 (pt) 2017-07-04
EP2890677A4 (en) 2016-03-09
CA2881797C (en) 2017-08-01
ES2651312T3 (es) 2018-01-25
IN2015MN00411A (enExample) 2015-09-04
EP2890677B1 (en) 2017-11-15
CA2881797A1 (en) 2014-03-06
KR101561987B1 (ko) 2015-10-20
MX368381B (es) 2019-09-30
CN104755460A (zh) 2015-07-01
AU2013309723A1 (en) 2015-02-26
RU2622651C2 (ru) 2017-06-19

Similar Documents

Publication Publication Date Title
CN106687450B (zh) 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法
US6028085A (en) Indole derivatives as 5-HT receptor antagonist
US8580817B2 (en) 1-(1-OXO-1,2,3,4-tetrahydroisoquinolin-7-YL)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
KR20200118062A (ko) 피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용
JP2015522062A (ja) 補体経路モジュレーターおよびその使用
KR20180123586A (ko) 피리미딘 유도체의 제조 방법
KR100496220B1 (ko) 세포 증식 억제제로서의 시아노구아니딘
CN104169254A (zh) 作为n-甲酰肽样受体-1(fprl-1)受体的调节剂的芳基脲衍生物
JP2016535042A (ja) ２−ベンジル−ベンゾイミダゾール補体因子ｂ阻害剤およびその使用
JP6831324B2 (ja) 特定のタンパク質キナーゼ阻害剤
KR100549631B1 (ko) 시아노구아니딘, 이의 제조방법 및 이를 함유하는 약제학적 제제
PH12015500282B1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
TWI829329B (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
KR20220044753A (ko) 아세틸 조효소 a 신테타제 단쇄 2(acss2)의 소분자 억제제
UA128087C2 (uk) Заміщені алкініленові сполуки як протипухлинні засоби
CN111372936B (zh) Mcl-1选择性抑制剂及其制备和用途
RU2248969C2 (ru) Азотсодержащие гетероциклические производные, фармацевтическая композиция на их основе и противораковый агент
KR20140096083A (ko) 림프증식성 악성종양의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제로서 ｎ­（3­｛［（3­｛［2­클로로­5­（메톡시）페닐］아미노｝퀴녹살린­2­일）아미노］설포닐｝페닐）­2­메틸알라닌아미드
EP2970239A1 (en) Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators
WO2010000429A1 (en) Adenine receptor ligands
JP2018523660A (ja) ベンゾジアゼピン誘導体の合成
CN108863948A (zh) 嘧啶取代的酰肼衍生物及其用途